News

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that positive results from in vivo and in vitro research, using its specific Sortilin receptor platform for the treatment of triple-negative breast cancer and ovarian cancer, were published on-line in two abstracts as part of the American Society of Clinical Oncology (“ASCO”) annual conference.